Highest-materiality recent filing
Jennifer Taubert, EVP and Worldwide Chairman of Innovative Medicine, to retire Sept 1, 2026
Jennifer Taubert retiring as EVP, Worldwide Chairman of Innovative Medicine and member of Executive Committee.
JNJ completes Firefly acquisition, enters Sail collaboration; cuts 2026 EPS guidance by $0.64
2026 adjusted operational EPS midpoint lowered to $10.94 from $11.58; adjusted EPS midpoint to $11.04 from $11.68.
Johnson & Johnson agrees to $5.5B comprehensive resolution of ovarian talc litigation
Agreement with plaintiff firms leading federal MDL and state court proceedings, conditioned on at least 95% participation of remaining claims.
JNJ Q2 2026 revenue up 6.6% to $25.3B; adjusted EPS $2.90 (+4.7%)
Q2 sales $25,310M (+6.6% operational, +1.0% currency); GAAP net earnings $5,534M (-0.1%).
JNJ Q1 adj. EPS $2.70 (down 1.4% YoY); raises dividend 3.1% to $1.34/qtr
Q1 revenue $24.06B, up 9.9% YoY (operational growth 6.4%, currency 3.5%).
JNJ Q4 2025 sales $24.6B (+9.1% YoY), net earnings $5.1B ($2.10 EPS); adj. EPS $2.46
Q4 sales $24,564M (+9.1% YoY); full-year sales $94,193M (+6.0% YoY).
JNJ reports Q3 adjusted EPS $2.80; plans to spin off Orthopaedics as DePuy Synthes
Q3 revenue $23,993M (+6.8% YoY); GAAP EPS $2.12, adjusted EPS $2.80 (+15.7% YoY).
JNJ Q2 sales $23.7B (+5.8%); GAAP EPS $2.29 (+18.7%); adj. EPS $2.77 (-1.8%)
Q2 sales $23,743M (+5.8% YoY); U.S. $13,544M (+7.8%), International $10,199M (+3.2%).
JNJ Q1 adj EPS $2.77 (+2.2%), revenue $21.9B; dividend +4.8% to $1.30
GAAP net earnings $11.0B ($4.54 diluted EPS) vs $3.3B ($1.34), boosted by $7.3B other income.
Bankruptcy court denies J&J's Red River Talc prepackaged plan; $7B reserve reversed
U.S. Bankruptcy Court for Southern District of Texas denied confirmation of Red River Talc LLC's prepackaged plan on March 31, 2025.
Johnson & Johnson completes €4B multi-tranche euro note offering
Issued €600M 2.700% Notes due 2029, €700M 3.050% Notes due 2033, and €1B 3.350% Notes due 2037.
Issued $750M 4.500% notes due 2027, $750M 4.550% notes due 2028, and $1B 4.700% notes due 2030.
JNJ Q4 net earnings down 17%, revenue up 5.3% to $22.52B; adjusted EPS $2.04
Q4 sales $22.52B, +5.3% YoY; net earnings $3.43B, -17% from $4.13B; diluted EPS $1.41.
Worldwide sales $22.47B (+5.2% reported, +6.3% operational); MedTech up 5.8%, Innovative Medicine up 4.9%.
Red River Talc LLC filed voluntary prepackaged Chapter 11 in Southern District of Texas.
J&J Q2 revenue up 4.3% but GAAP EPS falls 5.9%; adjusted EPS rises 10.2%
Q2 2024 revenue $22.4B, +4.3% YoY; GAAP diluted EPS $1.93, -5.9% YoY; adjusted diluted EPS $2.82, +10.2% YoY.
Johnson & Johnson fully divests remaining Kenvue stake via debt-for-equity exchange
On May 17, 2024, JNJ exchanged its remaining 182.3M Kenvue shares for $3.6B commercial paper, eliminating its Kenvue ownership.
JNJ proposes $6.475B talc settlement plan; Q1 GAAP EPS cut to $1.34
Proposed plan pays $6.475B present value ($8.4B nominal over 25 years) to resolve all ovarian cancer cosmetic talc claims.
JNJ reports Q1 adjusted EPS $2.71 (+12.4% YoY); declares 4.2% dividend increase to $1.24/quarter
Worldwide sales $21.38B, up 2.3% total (6.0% ex-COVID-19 vaccine); MedTech up 4.5%, Innovative Medicine ex-vaccine up 6.9%
JNJ Q4 2023 revenue $21.4B (+7.3% YoY), adjusted EPS $2.29 (+11.7%)
Q4 sales $21,395M (+7.3% YoY); FY 2023 sales $85,159M (+6.5% YoY).
JNJ completes Laminar acquisition for $400M upfront; cuts FY2023 adjusted EPS guidance by $0.17
Upfront payment of $400M (subject to adjustments) plus potential clinical/regulatory milestone payments.
JNJ Q3 adjusted EPS $2.66 rises 19% YoY; $21.7B gain from Kenvue separation
Q3 sales $21.35B (+6.8% YoY); adjusted diluted EPS $2.66 (+19.3% YoY from $2.23).
JNJ updates 2023 guidance post-Kenvue separation; raises sales & EPS outlook, cuts share count
Updated 2023 guidance: Reported Sales Growth 7.0%-8.0%, Adjusted EPS $10.00-$10.10 (12.5% growth at midpoint).
Johnson & Johnson completes split-off exchange of 1.53B Kenvue shares for 190.96M JNJ shares
Completed split-off exchange offer on Aug 23, 2023: exchanged 1,533,830,450 Kenvue shares for 190,955,435 JNJ shares.
JNJ Q2 preliminary: sales $25.53B (+6.3%), EPS $1.96 (+8.9%)
Net earnings $5.14B vs $4.81B; diluted EPS $1.96 vs $1.80 YoY.
JNJ Q2 sales up 6.3% to $25.5B; raises FY guidance; Kenvue spin-off via exchange offer
Q2 2023 sales $25.53B (+6.3%); operational sales growth 7.5% excluding COVID-19 vaccine 8.9%.
J&J completes Kenvue IPO at $22/share, retains 89.6% stake; net proceeds $4.24B
Kenvue IPO priced at $22.00 per share; 198.7M shares sold including over-allotment.
J&J Q1 revenue $24.7B (+5.6%), adj EPS $2.68 (+0.4%); raises FY guidance, increases dividend 5.3%
GAAP net loss $68M ($0.03 loss per share) due to $7.2B one-time charge; adjusted net earnings $7,068M, adj EPS $2.68.
J&J subsidiary LTL re-files Chapter 11; J&J commits $8.9B to resolve talc claims
LTL re-filed for Chapter 11 bankruptcy to resolve all cosmetic talc claims against J&J in North America.
J&J Q4 sales fall 4.4% to $23.7B; adjusted EPS rises 10.3% to $2.35; 2023 guidance issued
Q4 reported sales $23.7B, -4.4% YoY; operational growth ex-COVID vaccine +4.6%.
JNJ completes $16.6B acquisition of Abiomed; $380/sh + CVR up to $35/sh
Tender offer expired with ~57.1% of shares tendered; all conditions satisfied.
D. Adamczyk notified the Company that he intends to retire from the Company’s Board of Directors in connection with an announcement on April 23 rd that he will join Goldman Sachs as a Partner.
On September 10, 2024, D. S. Davis retired as a Director of Johnson & Johnson after the successful transition of Audit Committee Chair responsibilities to D. Adamczyk.
On August 26, 2024, Johnson & Johnson (the Company) issued a press release announcing that Peter M. Fasolo, Executive Vice President, Chief Human Resources Officer (CHRO), has elected to retire.
On November 30, 2023, Johnson & Johnson (the “Company” or “Johnson & Johnson”) announced that Eugene A. Woods, MBA, MHA, was elected to the Board of Directors.
Ashley McEvoy resigned from her position as Executive Vice President, Worldwide Chair MedTech and member of the Executive Committee effective October 20, 2023
Upon the closing of the initial public offering of Kenvue Inc., Thibaut Mongon will cease to be Executive Vice President, Worldwide Chairman, Consumer Health and member of the Executive Committee of Johnson & Johnson and will continue his role as Chief Executive Officer of Kenvue Inc.
On March 31, 2023, Ian E. L. Davis retired as a Director of Johnson & Johnson.
Johnson & Johnson (the “Company”) announced on February 14, 2023, that Paula A. Johnson, President of Wellesley College, has been appointed to its Board of Directors (the “Board”), effective immediately.
Johnson & Johnson (the “Company”) announced on February 14, 2023, that Paula A. Johnson, Chairman and Chief Executive Officer of Honeywell, has been appointed to its Board of Directors (the “Board”), effective immediately.
Current Chairman Alex Gorsky will step down from the Board in January 2023, following a brief transition period and will not stand for reelection in 2023.
the Company announced that its Board of Directors elected Joaquin Duato Chairman, Board of Directors of Johnson & Johnson effective upon current Chairman Alex Gorsky’s retirement from the Board of Directors.
Johnson & Johnson (the “Company”) announced on February 15, 2022, that Darius Adamczyk, Chairman and Chief Executive Officer of Honeywell, has been appointed to its Board of Directors (the “Board”), effective immediately.
Max materiality 0.90 · Median 0.65 · Most common event earnings